1. Food and Drug Administration. FDA Drug Safety Communication: Updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer. 2016. https://www.fda.gov/Drugs/DrugSafety/ucm519616.htm
2. Yoshimura R, Matsuyama M, Segawa Y, et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003;104(5):597–602. DOI: 10.1002/ijc.10980
3. Mearns ES, Sobieraj DM, White CM, et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. PLoS One. 2015;10(4):e0125879. DOI: 10.1371/journal.pone.0125879
4. Burger M, Catto JWF, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234–241. DOI: 10.1016/j.eururo.2012.07.033
5. Kakehi Y, Hirao Y, Kim WJ, et al. Bladder Cancer Working Group report. Jpn J Clin Oncol. 2010;40(Suppl 1):i57–64. DOI: 10.1093/jjco/hyq128.
6. Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ. 2012;344:e3645. DOI: 10.1136/bmj.e3645
7. Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. JAMA. 2015;314(3):265-277. DOI:10.1001/jama.2015.7996
8. Wei L, MacDonald TM, Mackenzie IS. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol. 2012;75(1):254-259. DOI: 10.1111/j.1365-2125.2012.04325.x
9. Dormandy JA, Charbonnel B, Eckland DA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279–1289. DOI: 10.1016/S0140-6736(05)67528-9
10. Filipova E, Uzunova K, Kalinov K, Vekov T. Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis. Diabetes Ther. 2017;8:705–726. DOI: 10.1007/s13300-017-0273-4
11. Zhu Z, Shen Z, Lu Y, et al. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A meta-analysis. Diabetes Research and Clinical Practice. 2012;98:159-163. DOI: 10.1016/j.diabres.2012.05.006
12. Adil M, Khan RA, Gosh P, et al. Pioglitazone and risk of bladder cancer in type 2 diabetes mellitus patients: A systematic literature review and meta-analysis of observational studies using real-world data. Clin Epidemiol Glob Health. 2017 DOI: 10.1016/j.cegh.2017.08.002